Comparison of chromogenic in situ hybridization with other methodologies for HER2 status assesment in breast cancer

Journal of Molecular Histology

Volumn 35, Issue 6, 2004, Pages 647-653

  Hauser Kronberger, Cornelia ^a   Dandachi, Nadia ^b  

^a St Johanns Spital   (Austria)

^b MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2;

BREAST CANCER; CANCER CELL; CARCINOMA IN SITU; COHORT ANALYSIS; CONFERENCE PAPER; CONTROLLED STUDY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; INCIDENCE; INTERMETHOD COMPARISON; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TISSUE DIFFERENTIATION; ARTICLE; BREAST TUMOR; COMPARATIVE STUDY; FEMALE; GENETICS; METABOLISM; METHODOLOGY; PATHOLOGY; PROTO ONCOGENE; RETROSPECTIVE STUDY;

BREAST NEOPLASMS; FEMALE; GENE AMPLIFICATION; GENES, ERBB-2; HUMANS; IN SITU HYBRIDIZATION; PROGNOSIS; RETROSPECTIVE STUDIES;

EID: 16644388989     PISSN: 15672379     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10735-004-2186-6     Document Type: Conference Paper

References (29)

1. Arnould L, Denoux Y, MacGrogan G, Penault-Llorca F, Fiche M, Treilleux I, Mathieu MC, Vincent-Salomon A, Vilain MO, Couturier J (2003) Agreement between chromogenic in situ hybridisation (CISH) and FISH in the determination of HER2 status in breast cancer. Br J Cancer 88: 1587-1591.
2. Bartlett JM, Going JJ, Mallon EA, Watters AD, Reeves JR, Stanton P, Richmond J, Donald B, Ferrier R, Cooke, TG (2001) Evaluating HER2 amplification and overexpression in breast cancer. J Pathol 195: 422-428.
3. Bartlett JM, Mallon E, Cooke T (2003) The clinical evaluation of HER-2 status: which test to use? J Pathol 199: 411-417.
4. Bieche I, Onody P, Laurendeau I, Olivi M, Vidaud D, Lidereau R, Vidaud M (1999) Real-time reverse transcription-PCR assay for future management of ERBB2-based clinical applications. Clin Chem 45: 1148-1156.
5. Bilous M, Dowsett M, Hanna W, Isola J, Lebeau A, Moreno A, Penault-Llorca F, Ruschoff J, Tomasic G, Van De Vijver M (2003) Current Perspectives on HER2 testing: A review of national testing guidelines. Mod Pathol 16: 173-182.
6. Dandachi N, Dietze O, Hauser-Kronberger C (2002) Chromogenic in situ hybridization: a novel approach to a practical and sensitive method for the detection of HER2 oncogene in archival human breast carcinoma. Lab Invest 82: 1007-1014.
7. Di Leo A, Dowsett M, Horten B, Penault-Llorca F (2002) Current status of HER2 testing. Oncology 63 (Suppl. 1): 25-32.
8. Dowsett M, Bartlett J, Ellis I, Salter J, Hills M, Mallon E, Watters A, Cooke T, Paish C, Wencyk P, Pinder S (2003) Correlation between immunohistochemistry (HercepTest) and fluorescence in situ hybridization (FISH) for HER-2 in 426 breast carcinomas from 37 centres. J Pathol 199: 418-423.
9. Foy CA, Parkes HC (2001) Emerging homogeneous DNA-based technologies in the clinical laboratory. Clin Chem 47: 990-1000.
10. Hanna WM, Kahn HJ, Pienkowska M, Blondal J, Seth A, Marks A (2001) Defining a test for HER-2/neu evaluation in breast cancer in the diagnostic setting. Mod Pathol 14: 677-685.
11. Johnson RC, Ricci A, Jr, Cartun RW, Ackroyd R, Tsongalis GJ (2000) p185HER2 overexpression in human breast cancer using molecular and immunohistochemical methods. Cancer Invest 18: 336-342.
12. Joensuu H, Isola J, Lundin M, Salminen T, Holli K, Kataja V, Pylkkanen L, Turpeenniemi-Hujanen T, von Smitten K, Lundin J (2003) Amplification of erbB2 and erbB2 expression are superior to estrogen receptor status as risk factors for distant recurrence in pT1N0M0 breast cancer: a nationwide population-based study. Clin Cancer Res 9: 923-930.
13. Konigshoff M, Wilhelm J, Bohle RM, Pingoud A, Hahn M (2003) HER-2/neu gene copy number quantified by real-time PCR: comparison of gene amplification, heterozygosity, and immunohistochemical status in breast cancer tissue. Clin Chem 49: 219-229.
14. Kumamoto H, Sasano H, Taniguchi T, Suzuki T, Moriya T, Ichinohasama R (2001) Chromogenic in situ hybridization analysis of HER-2/neu status in breast carcinoma: application in screening of patients for trastuzumab (Herceptin) therapy. Pathol Int 51: 579-584.
15. Lyon E, Millson A, Lowery MC, Woods R, Wittwer CT (2001) Quantification of HER2/neu gene amplification by competitive per using fluorescent melting curve analysis. Clin Chem 47: 844-851.
16. Millson A, Suli A, Hartung L, Kunitake S, Bennett A, Nordberg MC, Hanna W, Wittwer CT, Seth A, Lyon E (2003) Comparison of two quantitative polymerase chain reaction methods for detecting HER2/neu amplification. J Mol Diagn 5: 184-190.
17. Pauletti G, Godolphin W, Press MF, Slamon DJ (1996) Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization. Oncogene 13: 63-72.
18. Pegram MD, Pauletti G, Slamon DJ (1998) HER-2/neu as a predictive marker of response to breast cancer therapy. Breast Cancer Res Treat 52: 65-77.
19. Pellegrini C, Falleni M, Marchetti A, Cassani B, Miozzo M, Buttitta F, Roncalli M, Coggi G, Bosari S (2003) HER-2/Neu Alterations in Non-Small Cell Lung Cancer: A Comprehensive Evaluation by Real Time Reverse Transcription-PCR, Fluorescence in situ Hybridization, and Immunohistochemistry. Clin Cancer Res 9: 3645-3652.
20. Press MF, Bernstein L, Thomas PA, Meisner LF, Zhou JY, Ma Y, Hung G, Robinson RA, Harris C, El-Naggar A, Slamon DJ, Phillips RN, Ross JS, Wolman SR, Flora KJ (1997) HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. J Clin Oncol 15: 2894-2904.
21. Schnitt SJ, Jacobs TW (2001) Current status of HER2 testing: caught between a rock and a hard place. Am J Clin Pathol 116: 806-810.
22. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235: 177-182.
23. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A (1989) Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244: 707-712.
24. Tanner M, Gancberg D, Di Leo A, Larsimont D, Rouas G, Piccart MJ, Isola, J (2000) Chromogenic in situ hybridization: a practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples. Am J Pathol 157: 1467-1472.
25. Tubbs RR, Pettay JD, Roche PC, Stoler MH, Jenkins RB, Grogan TM (2001) Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: apparent immunohistochemical false-positives do not get the message. J Clin Oncol 19: 2714-2721.
26. Tubbs RR, Skacel M, Pettay J, Powell R, Myles J, Hicks D, Sreenan J, Roche P, Stoler MH, Hainfeld J (2002a). Interobserver interpretative reproducibility of GOLDFISH, a first generation gold-facilitated autometallographic bright field in situ hybridization assay for HER-2/neu amplification in invasive mammary carcinoma. Am J Surg Pathol 26: 908-913.
27. Tubbs RR, Pettay J, Skacel M, Powell R, Stoler M, Roche P, Hainfeld J (2002b) Gold-facilitated in situ hybridization: a bright-field autometallographic alternative to fluorescence in situ hybridization for detection of Her-2/neu gene amplification. Am J Pathol 160: 1589-1595.
28. Watters AD, Going JJ, Cooke TG, Bartlett JM (2003) Chromosome 17 aneusomy is associated with poor prognostic factors in invasive breast carcinoma. Breast Cancer Res Treat 77: 109-114.
29. Zhao J, Wu R, Au A, Marquez A, Yu Y, Shi Z (2002) Determination of HER2 Gene Amplification by Chromogenic In Situ Hybridization (CISH) in Archival Breast Carcinoma. Mod Pathol 15: 657-665.